Feed REC.MI
RE

Recordati Industria Chimica e Farmaceutica S.p.A.

REC.MI · MIL

52.10 € +0.19% (+0.10 €)
1M -0.95%
Market Cap 10.6B €
P/E Ratio 21.32x
Div. Yield 2.57%
ROE 24.74%

Bulios Fair Price

37.59 €

27.9% downside

Current Price

52.1 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, REC.MI is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
8/9
Valuation
54 /100
Fair
PEG 3.67x
P/E 21.32x
P/B 4.98x
Growth
71 /100
Growing
FCF growth 11.89%
EPS growth 12.47%
Book val. growth 7.48%
Profitability
100 /100
Strong
Op. margin 30.46%
Gross margin 70.74%
FCF margin 21.51%
Quality
78 /100
Excellent
ROA 9.26%
ROIC 13.55%
Asset turnover 0.50x
Debt
59 /100
Moderate
Int. coverage 7.71x
Debt/Equity 1.08x
Net debt/EBITDA 1.94x
Stability
96 /100
Stable
EPS volatility 10.44%
Beta 0.53x
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about REC.MI
Online

About the company

Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical company specializing in the development, manufacture, and distribution of drugs. The company focuses on the treatment of rare and chronic diseases in both the pharmaceutical and biotechnology sectors. Recordati operates globally, and its portfolio includes products in cardiovascular, neurological, endocrinological, and urological conditions. The company is also involved in research and development of new drugs and therapies to meet patient needs.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Robert Koremans

Employees

4,693

Headquarters

Milan

Upcoming events

10 NOV

Earnings

Upcoming earnings report

58d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.